Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

The Rate of Drug-Resistant Tuberculosis in Korean Children and Adolescents Since 2007.

Kim HJ, Yoon HH, Eun BW, Ahn Y, Ryoo S, Kim HJ.

J Korean Med Sci. 2017 Jun;32(6):954-960. doi: 10.3346/jkms.2017.32.6.954.

2.

Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.

de Vries G, Tsolova S, Anderson LF, Gebhard AC, Heldal E, Hollo V, Cejudo LS, Schmid D, Schreuder B, Varleva T, van der Werf MJ.

BMC Public Health. 2017 Apr 19;17(1):334. doi: 10.1186/s12889-017-4216-9.

3.

Multidrug resistant tuberculosis in prisons located in former Soviet countries: A systematic review.

Droznin M, Johnson A, Johnson AM.

PLoS One. 2017 Mar 23;12(3):e0174373. doi: 10.1371/journal.pone.0174373. eCollection 2017.

4.

Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis.

Ding P, Li X, Jia Z, Lu Z.

BMC Infect Dis. 2017 Jan 10;17(1):57. doi: 10.1186/s12879-016-2151-5.

5.

A Novel Motif for S-Adenosyl-l-methionine Binding by the Ribosomal RNA Methyltransferase TlyA from Mycobacterium tuberculosis.

Witek MA, Kuiper EG, Minten E, Crispell EK, Conn GL.

J Biol Chem. 2017 Feb 3;292(5):1977-1987. doi: 10.1074/jbc.M116.752659. Epub 2016 Dec 27.

PMID:
28031456
6.

Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa.

Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP.

PLoS One. 2016 Dec 1;11(12):e0165614. doi: 10.1371/journal.pone.0165614. eCollection 2016.

7.

Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?

Seung KJ, Franke M, Linton SW.

PLoS Med. 2016 Aug 2;13(8):e1002062. doi: 10.1371/journal.pmed.1002062. eCollection 2016 Aug.

8.

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai.

Udwadia ZF, Mullerpattan JB, Shah KD, Rodrigues CS.

Lung India. 2016 May-Jun;33(3):253-6. doi: 10.4103/0970-2113.180800.

9.

Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates.

Ferraz-Carvalho RS, Pereira MA, Linhares LA, Lira-Nogueira MC, Cavalcanti IM, Santos-Magalhães NS, Montenegro LM.

Mem Inst Oswaldo Cruz. 2016 May;111(5):330-4. doi: 10.1590/0074-02760150454. Epub 2016 Apr 29.

10.

Multidrug-Resistant TB as A Major Concern for Tuberculosis Control Programs.

Khazaei S, Salehiniya H, Soltani S, Mohammadian-Hafshejani A.

Iran J Public Health. 2016 Jan;45(1):114-5. No abstract available.

11.

Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS.

BMC Infect Dis. 2016 Feb 1;16:45. doi: 10.1186/s12879-016-1375-8.

12.

Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies.

Zwerling A, Shrestha S, Dowdy DW.

Adv Med. 2015;2015:907267. doi: 10.1155/2015/907267. Epub 2015 Mar 15. Review.

13.

The efficacy of negative pressure wound therapy in treating sacroiliac joint tuberculosis with a chronic sinus tract: a case series.

Luo X, Tang X, Ma Y, Zhang Y, Fang S.

J Orthop Surg Res. 2015 Aug 6;10:120. doi: 10.1186/s13018-015-0250-4.

14.

Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa.

Gilbert JA, Long EF, Brooks RP, Friedland GH, Moll AP, Townsend JP, Galvani AP, Shenoi SV.

PLoS One. 2015 May 4;10(5):e0126267. doi: 10.1371/journal.pone.0126267. eCollection 2015.

15.

Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.

Franke MF, Becerra MC, Tierney DB, Rich ML, Bonilla C, Bayona J, McLaughlin MM, Mitnick CD.

Ann Am Thorac Soc. 2015 May;12(5):674-9. doi: 10.1513/AnnalsATS.201411-538OC.

16.

Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment.

Tierney DB, Franke MF, Becerra MC, Alcántara Virú FA, Bonilla CA, Sánchez E, Guerra D, Muñoz M, Llaro K, Palacios E, Mestanza L, Hurtado RM, Furin JJ, Shin S, Mitnick CD.

PLoS One. 2014 Sep 19;9(9):e108035. doi: 10.1371/journal.pone.0108035. eCollection 2014.

17.

Management of MDR-TB: Review of Iran's Experience.

Masjedi MR, Tabarsi P, Marjani M, Shiva PB, Nasehi M, Gooya MM, Farnia P, Velayati AA.

Tanaffos. 2013;12(1):6-15. Review. No abstract available.

18.

Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis.

Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T, van der Walt M, Pagano M, Jensen P, Nardell E.

Int J Tuberc Lung Dis. 2014 Sep;18(9):1019-25. doi: 10.5588/ijtld.13.0834.

19.

Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.

Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S.

Clin Infect Dis. 2014 Jul 1;59(1):9-15. doi: 10.1093/cid/ciu209. Epub 2014 Apr 11.

20.

Bedaquiline metabolism: enzymes and novel metabolites.

Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X.

Drug Metab Dispos. 2014 May;42(5):863-6. doi: 10.1124/dmd.113.056119. Epub 2014 Feb 10.

Supplemental Content

Support Center